Document is current
Any future updates will be listed below
-
Authors
Calcagno, D. M. https://orcid.org/0000-0001-7022-9220
Taghdiri, N.
Ninh, V. K. https://orcid.org/0000-0001-6017-4035
Mesfin, J. M.
Toomu, A.
Sehgal, R. https://orcid.org/0000-0002-3609-7452
Lee, J.
Liang, Y.
Duran, J. M.
Adler, E.
Christman, K. L.
Zhang, K.
Sheikh, F.
Fu, Z.
King, K. R. https://orcid.org/0000-0003-1472-2189
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (T32HL105373, T32HL007444, HL142251, HL162369, R00HL129168)
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (DP2AR075321)
American Heart Association (AHA17IRG33410543)
- License Information
-
More Information
Article History
Received: 4 May 2022
Accepted: 3 October 2022
First Online: 17 November 2022
Competing interests
: F.S. is a cofounder and has an equity interest in Papillon Therapeutics; he is a consultant and has equity interest and a research grant from LEXEO Therapeutics. The other authors declare no competing interests.
